$吉利德科学(GILD)$ 算是告别JAK1了。。。

**Gilead will not pursue FDA approval for Jyseleca for Rheumatoid Arthritis (“RA”) in the United States.

**Galapagos will assume sole responsibility in Europe for Jyseleca for RA, UC and future indications; Gilead will receive royalties on European sales starting in 2024.

**Galapagos will assume responsibility for majority of ongoing clinical trials.